Skip to content

Arvinas ARVN Equity Method Income

Discontinued — last reported Q4 '25

Equity Method Income at other companies

Corvus Pharmaceuticals logo
Corvus PharmaceuticalsCRVS
-$599K-11.1%

Segments

By segment

See full
Reportable Segment$0

Other financials

Income statement

See full
Revenue$15.6M-91.7%
Operating income-$63.8M-189%
Net income-$57.6M-169%
EPS (diluted)-$0.90-179%

Balance sheet

See full
Cash & equivalents$87.3M+7.8%
Total debt$8.6M-19.6%
Total equity$386.8M-41.4%
Total assets$647.5M-35.3%

Cash flow

See full
Operating cash flow-$69.2M+22.2%
CapEx$1.3M+225%
Free cash flow-$70.5M+21.1%

Valuation

See full
Market cap$518.11M-4.6%
Enterprise value$439.41M-7.1%
P/S5.8×+4.5×

Profitability

See full
Operating margin-283.8%-310pp
Net margin-247.5%-260pp
FCF margin-287.4%

Returns & leverage

See full
Return on equity-42.3%-53.5pp
Debt / equity0.0×
Current ratio5.4×+0.9×

Where this comes from

Reported directly by Arvinas in its filing.

Tagged under the XBRL concept us-gaap:IncomeLossFromEquityMethodInvestments.

The official record: Arvinas’s 10-K, filed February 24, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arvinas's equity method income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arvinas's equity method income?
Arvinas (ARVN) reported equity method income of $0 in Q4 2025.
What is the long-term trend for Arvinas's equity method income?
Over 4 years (2021 to 2025), Arvinas's equity method income has grown at a -100.0% compound annual growth rate (CAGR), from -$6.9M to $0.
What does equity method income mean?
The company's proportional share of net income or loss from unconsolidated affiliates and joint ventures accounted for under the equity method.